Steven Cohen Morphic Holding, Inc. Transaction History

Point72 Asset Management, L.P.

$36.6 Billion
Q3 2024

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$26.12 - $34.07 $84.3 Million - $110 Million	-3,225,798 Reduced 68.82%	1,461,302 $49.8 Million
Q1 2024 May 15, 2024	BUY	$26.64 - $40.31 $2.56 Million - $3.87 Million	96,100 Added 2.09%	4,687,100 $165 Million
Q4 2023 Feb 14, 2024	BUY	$19.95 - $31.0 $41.6 Million - $64.7 Million	2,086,617 Added 83.32%	4,591,000 $133 Million
Q3 2023 Nov 14, 2023	BUY	$21.33 - $59.42 $53.4 Million - $149 Million	2,504,383 New	2,504,383 $57.4 Million
Q1 2023 May 15, 2023	BUY	$26.01 - $48.69 $2.32 Million - $4.35 Million	89,288 New	89,288 $3.36 Million
Q3 2022 Nov 14, 2022	SELL	$22.23 - $33.37 $6.46 Million - $9.7 Million	-290,600 Reduced 22.09%	1,024,700 $29 Million
Q2 2022 Aug 15, 2022	BUY	$19.74 - $43.01 $13.8 Million - $30 Million	697,866 Added 113.03%	1,315,300 $28.5 Million
Q1 2022 May 16, 2022	BUY	$36.25 - $52.02 $5.83 Million - $8.37 Million	160,934 Added 35.25%	617,434 $24.8 Million
Q4 2021 Feb 14, 2022	BUY	$43.27 - $65.72 $6.71 Million - $10.2 Million	155,015 Added 51.42%	456,500 $21.6 Million
Q3 2021 Nov 15, 2021	BUY	$53.61 - $67.5 $1.33 Million - $1.67 Million	24,785 Added 8.96%	301,485 $17.1 Million
Q2 2021 Aug 16, 2021	SELL	$45.13 - $64.99 $6.16 Million - $8.87 Million	-136,500 Reduced 33.03%	276,700 $15.9 Million
Q1 2021 May 17, 2021	BUY	$29.77 - $84.85 $1.58 Million - $4.51 Million	53,200 Added 14.78%	413,200 $26.1 Million
Q4 2020 Feb 16, 2021	BUY	$25.66 - $34.55 $4.59 Million - $6.18 Million	178,796 Added 98.67%	360,000 $12.1 Million
Q3 2020 Nov 16, 2020	BUY	$22.51 - $30.11 $4.08 Million - $5.46 Million	181,204 New	181,204 $4.95 Million

Others Institutions Holding MORF

# of Institutions

Shares Held

4.7M

Call Options Held

Put Options Held

View Full List

About Morphic Holding, Inc.

Ticker MORF
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 38,477,100
Market Cap $2.19B
Description
Morphic Holding, Inc., a biopharmaceutical company, discovers and develops oral small-molecule integrin therapeutics for the treatment of autoimmune, cardiovascular, metabolic diseases, as well as fibrosis and cancer. Its lead product candidates are MORF-057, an a4ß7-specific integrin inhibitor affecting inflammation that is in Phase 1 clinical ...

More about MORF

Track Steven Cohen's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Point72 Asset Management, L.P., based on Form 13F filings with the SEC.

News

Stay updated on Point72 Asset Management, L.P. and Steven Cohen with notifications on news.

Account